In the name of open science, the multinational scientific collaboration COSMOS on Thursday released the data behind the largest map of the universe. Called the COSMOS-Web field, the project, built with data collected by the James Webb Space Telescope (JWST), consists of all the imaging and a catalog of nearly 800,000 galaxies spanning nearly all of cosmic time. And it's been challenging existing notions of the infant universe.

"Our goal was to construct this deep field of space on a physical scale that far exceeded anything that had been done before," said UC Santa Barbara physics professor Caitlin Casey, who co-leads the COSMOS-Web collaboration alongside Jeyhan Kartaltepe of the Rochester Institute of Technology. "If you had a printout of the Hubble Ultra Deep Field on a standard piece of paper," she said, referring to the iconic view of nearly 10,000 galaxies released by NASA in 2004, "our image would be slightly larger than a 13-foot by 13-foot-wide mural, at the same depth. So it's really strikingly large."

The COSMOS-Web composite image reaches back about 13.5 billion years; according to NASA, the universe is about 13.8 billion years old, give or take one hundred million years. That covers about 98% of all cosmic time. The objective for the researchers was not just to see some of the most interesting galaxies at the beginning of time but also to see the wider view of cosmic environments that existed during the early universe, during the formation of the first stars, galaxies and black holes.

"The cosmos is organized in dense regions and voids," Casey explained. "And we wanted to go beyond finding the most distant galaxies; we wanted to get that broader context of where they lived."

A 'big surprise'

And what a cosmic neighborhood it turned out to be. Before JWST turned on, Casey said, she and fellow astronomers made their best predictions about how many more galaxies the space telescope would be able to see, given its 6.5 meter (21 foot) diameter light-collecting primary mirror, about six times larger than Hubble's 2.4 meter (7 foot, 10 in) diameter mirror. The best measurements from Hubble suggested that galaxies within the first 500 million years would be incredibly rare, she said.

"It makes sense -- the Big Bang happens and things take time to gravitationally collapse and form, and for stars to turn on. There's a timescale associated with that," Casey explained. "And the big surprise is that with JWST, we see roughly 10 times more galaxies than expected at these incredible distances. We're also seeing supermassive black holes that are not even visible with Hubble." And they're not just seeing more, they're seeing different types of galaxies and black holes, she added.

'Lots of unanswered questions'

While the COSMOS-Web images and catalog answer many questions astronomers have had about the early universe, they also spark more questions.

"Since the telescope turned on we've been wondering 'Are these JWST datasets breaking the cosmological model? Because the universe was producing too much light too early; it had only about 400 million years to form something like a billion solar masses of stars. We just do not know how to make that happen," Casey said. "So, lots of details to unpack, and lots of unanswered questions."

In releasing the data to the public, the hope is that other astronomers from all over the world will use it to, among other things, further refine our understanding of how the early universe was populated and how everything evolved to the present day. The dataset may also provide clues to other outstanding mysteries of the cosmos, such as dark matter and physics of the early universe that may be different from what we know today.

"A big part of this project is the democratization of science and making tools and data from the best telescopes accessible to the broader community," Casey said. The data was made public almost immediately after it was gathered, but only in its raw form, useful only to those with the specialized technical knowledge and the supercomputer access to process and interpret it. The COSMOS collaboration has worked tirelessly for the past two years to convert raw data into broadly usable images and catalogs. In creating these products and releasing them, the researchers hope that even undergraduate astronomers could dig into the material and learn something new.

"Because the best science is really done when everyone thinks about the same data set differently," Casey said. "It's not just for one group of people to figure out the mysteries."

For the COSMOS collaboration, the exploration continues. They've headed back to the deep field to further map and study it.

"We have more data collection coming up," she said. "We think we have identified the earliest galaxies in the image, but we need to verify that." To do so, they'll be using spectroscopy, which breaks up light from galaxies into a prism, to confirm the distance of these sources (more distant = older). "As a byproduct," Casey added, "we'll get to understand the interstellar chemistry in these systems through tracing nitrogen, carbon and oxygen. There's a lot left to learn and we're just beginning to scratch the surface."

The COSMOS-Web image is available to browse interactively; the accompanying scientific papers have been submitted to the Astrophysical Journal and Astronomy & Astrophysics.

Read more …Largest-ever map of the universe reveals 10x more early galaxies than expected

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published on June 4 by The BMJ.

The results show that treatment with dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) -- a condition where excess fat accumulates in the liver, leading to inflammation -- and liver fibrosis (a build up of scar tissue) compared with placebo.

MASH affects more than 5% of adults, more than 30% of individuals with diabetes or obesity, and can progress to cirrhosis in up to 25% of individuals.

Several studies have reported that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, but no trial has been carried out among patients with MASH.

To address this, researchers enrolled 154 adults (average age 35; 85% men) diagnosed with MASH after a liver biopsy at six medical centers in China from November 2018 to March 2023.

Almost half (45%) had type 2 diabetes, and almost all had liver fibrosis (33% stage 1, 45% stage 2, 19% stage 3).

After an initial screening biopsy, participants were randomly assigned to receive 10 mg of dapagliflozin or matching placebo once daily for 48 weeks and attended health education sessions twice a year.

Various factors including body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids were also assessed at enrollment and throughout the trial.

MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less.

After an end of study biopsy at week 48, 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group.

Resolution of MASH without worsening of fibrosis occurred in 23% (18 of 78) participants in the dapagliflozin group compared with 8% (6 of 76) in the placebo group.

Fibrosis improvement without worsening of MASH was also reported in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group.

The percentage of participants who discontinued treatment because of adverse events was 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group.

The researchers acknowledge that the trial was conducted in a Chinese population, which limits its broader generalizability, and that female and older patients were under-represented. But they point out that results were consistent after further analyses, suggesting they are robust.

As such, they conclude: "Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis." Large scale and long term trials are needed to further confirm these effects, they add.

The coming years are expected to be particularly exciting in the field of pharmacological treatment for MASH, say researchers from Argentina in a linked editorial.

As more drugs become available, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. "Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations," they conclude.

Read more …Clinical trial finds diabetes pill reduces liver scarring

More Articles …